Efficacy of Valganciclovir in the Treatment of Cytomegalovirus Disease in Kidney and Pancreas Transplant Recipients

F. L. Luan, Pavan Chopra, J. Park, S. Norman, D. Cibrik, A. Ojo

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Cytomegalovirus (CMV) disease is relatively common following solid organ transplant, particularly if a serologically negative recipient receives an organ from a serologically positive donor (D+/R-). Although valganciclovir is approved for the treatment of CMV retinitis in AIDS patients and is used for the prophylaxis against CMV infection in solid organ transplant patients, the current standard treatment for CMV disease in solid organ transplant recipients remains intravenous ganciclovir. We retrospectively reviewed our experience using valganciclovir as treatment for CMV disease in CMV D+/R- kidney and/or pancreas transplant recipients from March 2002 to June 2005. A total of 37 cases with primary CMV disease were diagnosed and treated with either intravenous ganciclovir as induction followed with valganciclovir or valganciclovir from the beginning. We compared clinical outcomes and viremia between the two groups. Our data suggest that valganciclovir is an effective treatment modality for primary CMV disease in kidney and/or pancreas transplant recipients. It led to the resolution of disease and undetectable viremia. Valganciclovir allowed for early initiation of treatment and for treatment to be given as an outpatient. These advantages of valganciclovir have both health and economic impact for patients with CMV disease.

Original languageEnglish (US)
Pages (from-to)3673-3675
Number of pages3
JournalTransplantation Proceedings
Volume38
Issue number10
DOIs
StatePublished - Dec 2006
Externally publishedYes

Fingerprint

Kidney Diseases
Cytomegalovirus
Pancreas
Ganciclovir
Viremia
Transplants
Therapeutics
Cytomegalovirus Retinitis
Cytomegalovirus Infections
valganciclovir
Transplant Recipients
Acquired Immunodeficiency Syndrome
Outpatients
Economics
Tissue Donors
Kidney
Health

ASJC Scopus subject areas

  • Surgery
  • Transplantation

Cite this

Efficacy of Valganciclovir in the Treatment of Cytomegalovirus Disease in Kidney and Pancreas Transplant Recipients. / Luan, F. L.; Chopra, Pavan; Park, J.; Norman, S.; Cibrik, D.; Ojo, A.

In: Transplantation Proceedings, Vol. 38, No. 10, 12.2006, p. 3673-3675.

Research output: Contribution to journalArticle

Luan, F. L. ; Chopra, Pavan ; Park, J. ; Norman, S. ; Cibrik, D. ; Ojo, A. / Efficacy of Valganciclovir in the Treatment of Cytomegalovirus Disease in Kidney and Pancreas Transplant Recipients. In: Transplantation Proceedings. 2006 ; Vol. 38, No. 10. pp. 3673-3675.
@article{b5fd03e62a844a1f9838015f85688b16,
title = "Efficacy of Valganciclovir in the Treatment of Cytomegalovirus Disease in Kidney and Pancreas Transplant Recipients",
abstract = "Cytomegalovirus (CMV) disease is relatively common following solid organ transplant, particularly if a serologically negative recipient receives an organ from a serologically positive donor (D+/R-). Although valganciclovir is approved for the treatment of CMV retinitis in AIDS patients and is used for the prophylaxis against CMV infection in solid organ transplant patients, the current standard treatment for CMV disease in solid organ transplant recipients remains intravenous ganciclovir. We retrospectively reviewed our experience using valganciclovir as treatment for CMV disease in CMV D+/R- kidney and/or pancreas transplant recipients from March 2002 to June 2005. A total of 37 cases with primary CMV disease were diagnosed and treated with either intravenous ganciclovir as induction followed with valganciclovir or valganciclovir from the beginning. We compared clinical outcomes and viremia between the two groups. Our data suggest that valganciclovir is an effective treatment modality for primary CMV disease in kidney and/or pancreas transplant recipients. It led to the resolution of disease and undetectable viremia. Valganciclovir allowed for early initiation of treatment and for treatment to be given as an outpatient. These advantages of valganciclovir have both health and economic impact for patients with CMV disease.",
author = "Luan, {F. L.} and Pavan Chopra and J. Park and S. Norman and D. Cibrik and A. Ojo",
year = "2006",
month = "12",
doi = "10.1016/j.transproceed.2006.10.105",
language = "English (US)",
volume = "38",
pages = "3673--3675",
journal = "Transplantation Proceedings",
issn = "0041-1345",
publisher = "Elsevier USA",
number = "10",

}

TY - JOUR

T1 - Efficacy of Valganciclovir in the Treatment of Cytomegalovirus Disease in Kidney and Pancreas Transplant Recipients

AU - Luan, F. L.

AU - Chopra, Pavan

AU - Park, J.

AU - Norman, S.

AU - Cibrik, D.

AU - Ojo, A.

PY - 2006/12

Y1 - 2006/12

N2 - Cytomegalovirus (CMV) disease is relatively common following solid organ transplant, particularly if a serologically negative recipient receives an organ from a serologically positive donor (D+/R-). Although valganciclovir is approved for the treatment of CMV retinitis in AIDS patients and is used for the prophylaxis against CMV infection in solid organ transplant patients, the current standard treatment for CMV disease in solid organ transplant recipients remains intravenous ganciclovir. We retrospectively reviewed our experience using valganciclovir as treatment for CMV disease in CMV D+/R- kidney and/or pancreas transplant recipients from March 2002 to June 2005. A total of 37 cases with primary CMV disease were diagnosed and treated with either intravenous ganciclovir as induction followed with valganciclovir or valganciclovir from the beginning. We compared clinical outcomes and viremia between the two groups. Our data suggest that valganciclovir is an effective treatment modality for primary CMV disease in kidney and/or pancreas transplant recipients. It led to the resolution of disease and undetectable viremia. Valganciclovir allowed for early initiation of treatment and for treatment to be given as an outpatient. These advantages of valganciclovir have both health and economic impact for patients with CMV disease.

AB - Cytomegalovirus (CMV) disease is relatively common following solid organ transplant, particularly if a serologically negative recipient receives an organ from a serologically positive donor (D+/R-). Although valganciclovir is approved for the treatment of CMV retinitis in AIDS patients and is used for the prophylaxis against CMV infection in solid organ transplant patients, the current standard treatment for CMV disease in solid organ transplant recipients remains intravenous ganciclovir. We retrospectively reviewed our experience using valganciclovir as treatment for CMV disease in CMV D+/R- kidney and/or pancreas transplant recipients from March 2002 to June 2005. A total of 37 cases with primary CMV disease were diagnosed and treated with either intravenous ganciclovir as induction followed with valganciclovir or valganciclovir from the beginning. We compared clinical outcomes and viremia between the two groups. Our data suggest that valganciclovir is an effective treatment modality for primary CMV disease in kidney and/or pancreas transplant recipients. It led to the resolution of disease and undetectable viremia. Valganciclovir allowed for early initiation of treatment and for treatment to be given as an outpatient. These advantages of valganciclovir have both health and economic impact for patients with CMV disease.

UR - http://www.scopus.com/inward/record.url?scp=33845468280&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845468280&partnerID=8YFLogxK

U2 - 10.1016/j.transproceed.2006.10.105

DO - 10.1016/j.transproceed.2006.10.105

M3 - Article

C2 - 17175363

AN - SCOPUS:33845468280

VL - 38

SP - 3673

EP - 3675

JO - Transplantation Proceedings

JF - Transplantation Proceedings

SN - 0041-1345

IS - 10

ER -